Which AI agents work with Endo Ascvd Risk Assessment Guide Lipid Therapy Obesity?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Who published Endo Ascvd Risk Assessment Guide Lipid Therapy Obesity?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo Ascvd Risk Assessment Guide Lipid Therapy Obesity by dromlakhani

Name: Endo Ascvd Risk Assessment Guide Lipid Therapy Obesity
Rating: 4.2 (5 reviews)
Author: dromlakhani

Endo Ascvd Risk Assessment Guide Lipid Therapy Obesity

Recommends assessing 10-year atherosclerotic cardiovascular disease risk using the Pooled Cohort Equations to guide lipid-lowering therapy initiation in adults with obesity. Triggers include obese patient needing lipid-lowering therapy decision, assessing when to start statin in obesity, and using risk score to guide treatment in obesity.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

10-year ASCVD risk assessment to guide lipid-lowering therapy in obesity

STEP 1 — Gather Information

Collect data for Pooled Cohort Equations: age, sex, race, total cholesterol, HDL-C, systolic blood pressure, hypertension treatment status, diabetes status, smoking status; confirm obesity (BMI ≥30 kg/m2) and optionally waist circumference.
Action: Compile variables for 10-year ASCVD risk calculation.

STEP 2 — Rule In / Rule Out

Determine if patient has established ASCVD or long-standing diabetes. If yes, lipid-lowering therapy is indicated regardless of risk score (proceed to Decide). If no, proceed to calculate 10-year ASCVD risk.
Decision: Either initiate lipid-lowering therapy or continue to risk assessment.

STEP 3 — Classify or Stratify

Calculate 10-year ASCVD risk using Pooled Cohort Equations; categorize as low (<5%), borderline (5-7.4%), intermediate (7.5-19.9%), or high (≥20%). Assess for risk-enhancing factors: family history of premature ASCVD, elevated Lp(a) ≥50 mg/dL, metabolic syndrome, CKD, chronic inflammatory conditions, high-risk race/ethnicity.
Action: Assign risk category and document presence of risk-enhancing factors.

STEP 4 — Decide

Based on risk category and risk-enhancing factors: low risk (<5%) with no risk-enhancing factors → lifestyle therapy only; low risk with risk-enhancing factors → consider statin after clinician-patient discussion; borderline (5-7.4%) with risk-enhancing factors → recommend statin; intermediate (7.5-19.9%) or high (≥20%) → recommend statin; if uncertainty in borderline/intermediate risk, consider coronary artery calcium (CAC) scoring to reclassify.
Decision: Initiate or withhold lipid-lowering therapy (statin ± ezetimibe/PCSK9i) based on final risk stratification.

Clinical Guardrails / Mimics / Pitfalls

Do not rely solely on LDL-C thresholds without risk assessment in obesity; ensure smoking and hypertension treatment status are included in risk calculation; avoid using non-fasting triglycerides >500 mg/dL for LDL-C estimation without fasting confirmation; remember obesity itself is a risk-enhancing factor; do not use CAC=0 to avoid statin in high-risk patients with diabetes, familial hypercholesterolemia, or established ASCVD.

Concrete Clinical Example

58-year-old man with BMI 31, ex-smoker (quit 5 years ago), untreated hypertension (SBP 148), total cholesterol 210 mg/dL, HDL 38 mg/dL, no diabetes. 10-year ASCVD risk = 14.2% (intermediate). No additional risk-enhancing factors. Decision: initiate moderate-intensity statin therapy.

Source: Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674

TODO: consider adding scripts/calc.py for the endo-ascvd-risk-assessment-guide-lipid-therapy-obesity calculator

---name: endo-ascvd-risk-assessment-guide-lipid-therapy-obesitydescription: Recommends assessing 10-year atherosclerotic cardiovascular disease risk using the Pooled Cohort Equations to guide lipid-lowering therapy initiation in adults with obesity. Triggers include obese patient needing lipid-lowering therapy decision, assessing when to start statin in obesity, and using risk score to guide treatment in obesity.---# 10-year ASCVD risk assessment to guide lipid-lowering therapy in obesity## STEP 1 — Gather InformationCollect data for Pooled Cohort Equations: age, sex, race, total cholesterol, HDL-C, systolic blood pressure, hypertension treatment status, diabetes status, smoking status; confirm obesity (BMI ≥30 kg/m2) and optionally waist circumference. **Action:** Compile variables for 10-year ASCVD risk calculation.## STEP 2 — Rule In / Rule OutDetermine if patient has established ASCVD or long-standing diabetes. If yes, lipid-lowering therapy is indicated regardless of risk score (proceed to Decide). If no, proceed to calculate 10-year ASCVD risk. **Decision:** Either initiate lipid-lowering therapy or continue to risk assessment.## STEP 3 — Classify or StratifyCalculate 10-year ASCVD risk using Pooled Cohort Equations; categorize as low (<5%), borderline (5-7.4%), intermediate (7.5-19.9%), or high (≥20%). Assess for risk-enhancing factors: family history of premature ASCVD, elevated Lp(a) ≥50 mg/dL, metabolic syndrome, CKD, chronic inflammatory conditions, high-risk race/ethnicity. **Action:** Assign risk category and document presence of risk-enhancing factors.## STEP 4 — DecideBased on risk category and risk-enhancing factors: low risk (<5%) with no risk-enhancing factors → lifestyle therapy only; low risk with risk-enhancing factors → consider statin after clinician-patient discussion; borderline (5-7.4%) with risk-enhancing factors → recommend statin; intermediate (7.5-19.9%) or high (≥20%) → recommend statin; if uncertainty in borderline/intermediate risk, consider coronary artery calcium (CAC) scoring to reclassify. **Decision:** Initiate or withhold lipid-lowering therapy (statin ± ezetimibe/PCSK9i) based on final risk stratification.## Clinical Guardrails / Mimics / PitfallsDo not rely solely on LDL-C thresholds without risk assessment in obesity; ensure smoking and hypertension treatment status are included in risk calculation; avoid using non-fasting triglycerides >500 mg/dL for LDL-C estimation without fasting confirmation; remember obesity itself is a risk-enhancing factor; do not use CAC=0 to avoid statin in high-risk patients with diabetes, familial hypercholesterolemia, or established ASCVD.## Concrete Clinical Example58-year-old man with BMI 31, ex-smoker (quit 5 years ago), untreated hypertension (SBP 148), total cholesterol 210 mg/dL, HDL 38 mg/dL, no diabetes. 10-year ASCVD risk = 14.2% (intermediate). No additional risk-enhancing factors. Decision: initiate moderate-intensity statin therapy.**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674> **TODO:** consider adding scripts/calc.py for the endo-ascvd-risk-assessment-guide-lipid-therapy-obesity calculator

Frequently asked questions